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Abstract
Background: Hereditary tyrosinemia type 1 (HT1; MIM
276700) is caused by mutations in the fumarylaceto-
acetate hydrolase (FAH) gene, and is the most severe
disorder associated with the tyrosine catabolic path-
way. HT1 is a very rare disorder and no genetically
confirmed case of HT1 in Korea has yet been report-
ed. In this study, we present a Korean neonate with
clinical and biochemical features of HT1.
Methods: A female neonate was admitted to our
hospital for further work-up of an abnormal newborn
screening test. We analyzed amino acids and organic
acids in the patient’s blood and urine. To confirm the
presence of the genetic abnormality, all the coding
exons of the FAH gene and the flanking introns were
amplified by polymerase chain reaction (PCR).
Results: The patient’s newborn screening test
revealed increased concentrations of methionine and
tyrosine. Subsequent urine organic acid analysis
showed increased urinary excretion of 4-hydroxyphe-
nyllactate, 4-hydroxyphenylpyruvate, succinate, and
succinylacetone. Gap-PCR and sequence analysis of
the FAH gene revealed a homozygous large deletion
mutation encompassing exons 12–14. The patient’s
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parents were not consanguineous but were hetero-
zygous carriers of the same mutation.
Conclusions: The patient had a novel, large deletion
mutation of FAH and is the first report of genetically
confirmed HT1 in Korea.
Clin Chem Lab Med 2009;47:930–3.
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Introduction
Hereditary tyrosinemia type I (HT1, MIM 276700), also
referred to as hepato-renal tyrosinemia, is the most
severe disorder linked to the tyrosine catabolic path-
way (1). HT1 is caused by decreased activity of fuma-
rylacetoacetate hydrolase (FAH; EC 3.7.1.2), which is
the last enzyme that hydrolyzes fumarylacetoacetate
to fumarate and acetoacetate in the tyrosine catabolic
pathway (2, 3). FAH deficiency causes severe pro-
gressive liver disease in infancy, renal tubular defects
with hypophosphatemic rickets, and neurologic crises
(2). If not treated, patients usually die of liver failure
within the first year of life.
The worldwide prevalence of HT1 is known to be
very low (1:100,000–1:120,000 births); its prevalence
in Koreans is not known (4, 5). The human FAH gene
maps to the long arm of chromosome 15 in the region
q23–q25 and contains 14 exons that encode FAH
mRNA with a length of at least 1477 nucleotides (6,
7). There are variable levels of FAH enzyme activity in
liver tissue from patients with HT1 (8). The relation-
ship between genotype and phenotype is unclear,
because different clinical presentations of HT1 have
been reported in patients with identical genotypes (9).
Genotype heterogeneity is not sufficient for explain-
ing the clinical heterogeneity, and other factors may
modify the phenotype in HT1 (9).
In this report, we present the first biochemically and
genetically confirmed Korean patient with HT1. Inter-
estingly, the patient was homozygous for a novel
large deletion mutation of the FAH gene.
Materials and methods
Clinical and biochemical analysis
A female neonate was admitted to our hospital for further
evaluation of an abnormal newborn screening test per-
formed 2 days after birth at a local hospital. At 1 month
of age, the patient underwent various biochemical tests,
including total protein, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, ammonia, albumin,
bilirubin and lactate. In addition, tests in the newborn
screening test were confirmed by liquid chromatography-
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Figure 1 Gap-PCR results of the FAH gene.
Gap-PCR encompassing exons 12, 13 and 14 of the FAH gene
resulted in an expected amplicon of 18.5 kb, which was not
amplified from a control sample. A shorter 417 bp product
was detected in the patient, who has a homozygous large
deletion. The patient’s parents were carriers of this large
deletion.
tandem mass spectrometry (LC-MS/MS), and amino acids
and organic acids in the blood and urine were analyzed.
Abdominal ultrasonography was performed to visualize
abdominal anatomical structures.
Genetic analysis
The study was approved by the Ethical Committee of our
institution. Blood samples were collected from the patient
and parents after obtaining informed parental consent.
Genomic DNA was isolated from peripheral blood leuko-
cytes using the Wizard Genomic DNA Purification Kit (Pro-
mega, Madison, WI, USA). All of the coding exons of the FAH
gene and flanking introns were amplified using polymerase
chain reaction (PCR) with primers designed by the authors
(sequences available upon request) and a thermal cycler
(Model 9700; Applied Biosystems, Foster City, CA, USA). Five
microliters of amplification product were treated with 10 U
shrimp alkaline phosphatase and 2 U exonuclease I (USB
Corp., Cleveland, OH, USA). Direct sequencing was per-
formed with the ABI Prism 3100 Genetic Analyzer (Applied
Biosystems) using the BigDye Terminator Cycle Sequencing-
Ready Reaction Kit (Applied Biosystems). All novel muta-
tions were confirmed by testing 100 control chromosomes.
Gap-PCR
Gap-PCR using the AccuPower TLA PCR premix
(Bioneer, Daejeon, Korea) was performed since the patient
had a large deletion in the FAH gene. Using chromosomal
walking with different pairs of primers, the smallest PCR
amplicon (expected size: 18,453 bp) was detected using the
primer pair: forward (59-accctgttgctctttgcagt-39) and reverse
(39-gaaggagtcacccaatggaa-59). The primer sequences were
based on the intron sequences of the FAH gene obtained
from the Ensembl Genome Browser (http://www.ensembl.
org).
Results
Clinical and biochemical findings
The patient was born at 40 weeks’ gestation by vagi-
nal delivery and weighed 3.48 kg. Physical examina-
tion revealed an asymmetric face and hyperflexible
wrist joints. A repeat newborn screening test at 9 days
of life showed increased concentrations of phenylal-
anine, methionine and tyrosine: 155 mM phenylala-
nine (cut-off, F125 mM), 199 mM methionine (cut-off,
F67 mM) and 481 mM tyrosine (cut-off, F305 mM).
Liver function tests performed at 1 month of age
were also abnormal. Aspartate aminotransferase was
0.94 wreference range (RR) -0.53x mkat/L, alkaline
phosphatase was 1650 (RR, 42–98) U/L, ammonia was
89.3 (RR, 17.9–46.4) mmol/L, and lactate was 6.5
(RR, 0.5–2.2) mmol/L. Urine organic acid analysis at
1 month of age showed increased urinary excretion
of 4-hydroxyphenyllactate, 4-hydroxyphenylpyruvate,
succinate, and succinylacetone w4-hydroxyphenyl-
lactate: 893 mmol/mol creatinine (cut-off, -3), 4-
hydroxyphenylpyruvate: 563 mmol/mol creatinine
(cut-off, -1), succinate: 370 mmol/mol creatinine (cut-
off, -79), and succinylacetone: 28 mmol/mol creati-
nine (cut-off, non-detected)x. Abdominal ultrasound
revealed ascites and coarse parenchymal changes in
the liver.
The patient was diagnosed with HT1 based on
clinical and biochemical tests at 47 days after birth.
Treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione (NTBC) and dietary tyrosine
restriction was initiated after confirmation of tyrosi-
nemia type I. Following 1 week of treatment, the
patient’s increased urinary succinylacetone declined
to non-detectable concentrations and remained
-1 mmol/mol creatinine during follow-up. Urinary
concentrations of methionine and tyrosine reverted to
normal values of 5 mM and 11 mM, respectively, by
2 months of age. The patient’s disease was well con-
trolled, and she was seen as an outpatient.
At 4 months after birth, the patient developed acute
symptoms, including uncontrolled fever and dyspnea
suggestive of sepsis secondary to aspiration pneu-
monia. This developed independently of the patient’s
tyrosinemia. Although prompt management and
close observation was performed, septic complica-
tions including metabolic acidosis, ascites, and dis-
seminated intravascular coagulation developed and
the patient expired following cardiac arrest.
Genetic analysis
PCR of each FAH exon with intron primer failed to
amplify exons 12, 13, and 14, suggesting that the
patient was homozygous for a large deletion. Using
different primer pairs that covered the region from
intron 11 of the FAH gene to the FAH-ARNT2 inter-
genic region, gap-PCR was performed to identify the
breakpoint of the large deletion of exons 12, 13 and
14 (Figure 1). Sequence analysis of the PCR amplicon
revealed an 18,036 bp deleted region that spanned
from nucleotide 1130 of intron 11 of the FAH gene
to nucleotide 10,539 of the FAH-ARNT2 intergenic
region. According to the numbering position of the
human FAH reference sequence, the mutation could
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Figure 2 Breakpoint analysis of the deletion of exons 12–14 of the FAH gene.
Sequence analysis shows a deletion of 18,036 bp that spans from nucleotide 1130 of intron 11 of the FAH gene to nucleotide
10,539 of the FAH-ARNT2 intergenic region, designated as c.960q1130_*1260q10539del18036 (reference sequence from
NC_000015.8 and NM_000137.1).
be described as c.960q1130_*1260q10539del18036
(reference sequence from NC_000015.8 and NM_
000137.1) (Figure 2). The patient’s parents were car-
riers of this large deletion, and the patient inherited
one mutant allele from each parent. Screening of 50
normal controls revealed no mutant allele in 100
chromosomes.
Discussion
Currently, most laboratories perform newborn
screening tests using dried blood spots analyzed with
LC-MS/MS. However, this is a limited screening meth-
od for HT1 because tyrosine is increased in cases
of benign transient tyrosinemia. In addition, the
increased concentration of tyrosine in patients with
HT1 may overlap the normal range in control popu-
lations (4). Therefore, we determined the concentra-
tion of succinylacetone, a specific marker for HT1, in
dried blood spots using LC-MS/MS (10). The concen-
trations of methionine and tyrosine in this case were
not dramatically increased, but we diagnosed HT1
with the results from the analysis of urine organic
acids.
Although there have been a few reports of Korean
patients with tyrosinemia type 1 (11–13), all cases
were diagnosed by clinical and biochemical findings
without investigation of the molecular characteristics.
This is the first case in Korea of HT1 that was con-
firmed with genetic analysis in addition to the bio-
chemical abnormalities. In addition, the large deletion
identified in this study is a novel mutation. The most
common FAH gene mutations in patients with HT1
differ with respect to ethnicity. For example, the spe-
cific mutation IVS12q5G)A is prevalent in French
Canadian and Scandinavian, excluding Finnish, pop-
ulations (14, 15). In addition, five mutations IVS6-
1G)T, c.1009G)A, c.192G)T (a splicing error),
p.D233V, and p.W262X are common in Central and
Western Europe, Scandinavia, Pakistan, Turkey, and
Finland, respectively (15–18). These mutations are
thought to have spread by the founder effect.
In the FAH gene, missense and nonsense point
mutations, and splicing errors are common and
account for 90% of the total number of mutations
reported in the Human Gene Mutation Database
(HGMD) at the Institute of Medical Genetics in Cardiff
(http://www.hgmd.cf.ac.uk/ac/gene.php?genesFAH).
Large deletions of the FAH gene have rarely been
reported. Only one mutant allele with a large deletion,
E6/I6del26 (c.548_553q 20del), has been reported
previously (17). In the present study, we identified a
novel mutation, c.960q1130_*1260q10539del18036,
resulting in the loss of 100 residues (amino acids
321–420) from the protein. It was also interesting that
the patient’s parents were heterozygous carriers of
the same allele with a large deletion of the FAH gene.
The presence of a homozygous deletion in a non-con-
sanguineous pedigree is very unusual.
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Although the patient temporarily improved after
administration of NTBC, she died at 4 months of age
due to aspiration pneumonia and sepsis. NTBC is a
potent inhibitor of 4-hydroxyphenylpyruvate dioxy-
genase and has improved the outcomes of most
patients with hereditary tyrosinemia (19). The patient
was diagnosed clinically with an acute form of HT1,
given her presentation of hepatic signs and symp-
toms within the first 6 months of life (20). This clinical
presentation may be due to the large FAH deletion,
containing exons 12–14, which lead to the synthesis
of structurally unstable, incomplete proteins, thereby
inducing attenuation of FAH activity.
In summary, we diagnosed a Korean patient with
HT1 using biochemical and molecular analysis,
revealing a novel large-deletion FAH mutation. The
gap-PCR method developed in this study may be a
useful tool for the identification of Korean HT1
patients with deletions of exons 12–14.
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